CoChat

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease

Open access
Richard, Edo, den Brok, Melina G.H.E., van Gool, Willem A. · 2021 · Alzheimer's & Dementia
Cited by 50

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Numerous clinical trials of anti‐amyloid beta (Aβ) immunotherapy in Alzheimer's disease have been performed. None of these have provided convincing evidence for beneficial effects. Using traditional frequentist meta‐analysis, the conclusion is that there is absence of evidence for a therapeutic effect, with a point estimate effect size of 0.05 (95% confidence interval −0.00 to 0.10, P = .055). In addition, this non‐significant effect equates to 0.4 points per year on the cognitive subscale of the Alzheimer's Disease Assessment Scale. This is well below the minimally clinically important difference. Bayesian meta‐analysis of these trial data provides strong evidence of absence of a therapeutic effect, with a Bayes factor of 11.27 in favor of the null hypothesis, opposed to a Bayes factor of 0.09 in favor of a treatment effect. Bayesian analysis is particularly valuable in this context of repeatedly reported small, non‐significant effect sizes in individual trials. Mechanisms other than removal of Aβ from the brain may be probed to slow progression of Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/alz.12379

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 50

Metadata

Authors
Richard, E., den Brok, M. G. H. E., & van Gool, W. A.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2021-05-31
Volume
17
Issue
6
Pages
1051-1055
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W3165543316
Cited by
50
References
7
FWCI
5.74
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/alz.12379
The paper
Richard, E., den Brok, M. G. H. E., & van Gool, W. A. (2021). Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12379

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.